Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects-Reference-Cited by-同舟云学术

Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects

Published:2011-11-24 Issue:9 Volume:32 Page:525-529
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm. Drug Dispos.

Author:

Krishna Rajesh¹,Stypinski Daria²,Ali Melissa²,Garg Amit¹,Gendrano Isaias Noel¹,Maes Andrea¹,DeGroot Bruce²,Liu Yang¹,Li Susie¹,Connolly Sandra M.²,Wagner John A.¹,Stoch S. Aubrey¹

Affiliation:

1. Merck & Co., Inc.; Whitehouse Station; NJ; USA

2. Celerion; Lincoln; NE; USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/bdd.776/fullpdf

Reference12 articles.

1. Intensive versus moderate lipid lowering with statins after acute coronary syndromes;Cannon;N Engl J Med,2004

2. Safety of anacetrapib in patients with or at high risk for coronary heart disease;Cannon;N Engl J Med,2010

3. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients;Bloomfield;Am Heart J,2009

4. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies;Krishna;Lancet,2007

5. Digoxin for the treatment of chronic and acute heart failure syndromes;Gheorghiade;Acute Card Care,2009

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Amorphous Nanoparticle Size on Bioavailability of Anacetrapib in Dogs;Journal of Pharmaceutical Sciences;2019-09

2. Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects;The Journal of Clinical Pharmacology;2018-07-20

3. Success, Failure, and Transparency in Biomarker-Based Drug Development;Circulation: Cardiovascular Quality and Outcomes;2017-06

4. Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia;Expert Opinion on Drug Metabolism & Toxicology;2016-12-04

5. Anacetrapib;Cardiology in Review;2014-09